Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma

Phase 1 Terminated 47 enrolled GlaxoSmithKline

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate and compare the expression and change in expression of key severe asthma targets at baseline in mile to moderate asthmatics vs. severe asthmatic subjects. To evaluate and compare the airway pathology at baseline and changes in airway pathology in relation to asthma severity.

Timeline

Start: 2005-08-02
Primary completion: 2011-06-06
Completion: 2011-06-06

Outcome

Outcome not reported

Stopped (Enrollment): “The study was truncated due to the long period of enrollment and the collection of a sufficient amount of data that allowed the scientific objectives to be met”

Publications

Siddiqui S, Shikotra A, Richardson M, Doran E, Choy D, Bell A, Austin CD, Eastham-Anderson J, Hargadon B, Arron JR, Wardlaw A, Brightling CE, Heaney LG, Bradding P. Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis. J Allergy Clin Immunol. 2018 Nov;142(5):1457-1468. doi: 10.1016/j.jaci.2017.12.982. Epub 2018 Mar 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prednisolone	Other / unclassified	0.5 mg/kg	Oral